Common Cholesteryl Ester Transfer Protein Mutations, Decreased HDL Cholesterol, and Possible Decreased Risk of Ischemic Heart Disease: The Copenhagen City Heart Study

BackgroundCholesteryl ester transfer protein (CETP) mediates the transfer of cholesteryl ester from HDL in exchange for triglycerides in apolipoprotein B–containing lipoproteins. Methods and ResultsWe studied 2 common mutations in CETP, A373P and R451Q, in 8467 healthy women and men from the Danish general population and in 1636 Danish women and men with ischemic heart disease. The prevalence of 373P and 451Q was 0.10 and 0.07, respectively, for heterozygous carriers and 0.003 and 0.002, respectively, for homozygous carriers. All carriers of the 451Q allele also carried the 373P allele. HDL cholesterol in female noncarriers, heterozygotes, and homozygotes of 373P was 1.74±0.01 (mean±SE), 1.62±0.02, and 1.38±0.09 mmol/L, respectively (ANOVA, P <0.001). In men, equivalent values were 1.40±0.01, 1.26±0.02, and 1.19±0.09 mmol/L, respectively (ANOVA, P <0.001). HDL cholesterol decreased similarly as a function of 451Q genotypes and all 373P/451Q genotype combinations. Furthermore, apolipoprotein AI and the HDL cholesterol/apolipoprotein AI ratio was also lower in carriers of either of these mutations for both sexes. Finally, the CETP genotype was not associated with risk of ischemic heart disease unless we adjusted for HDL cholesterol: female heterozygous and homozygous carriers versus noncarriers had 36% lower risk of ischemic heart disease (95% CI 4% to 57%); in male carriers, we observed a similar trend. ConclusionsThe A373P/R451Q polymorphism in CETP is associated with decreases in HDL cholesterol of 0.12 to 0.36 mmol/L in women and 0.14 to 0.21 mmol/L in men and possibly with a paradoxical 36% decrease in the risk of ischemic heart disease in women.

[1]  G. Jensen,et al.  Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. , 2000, Circulation.

[2]  P. Talmud,et al.  Genotypic associations of the hepatic secretion of VLDL apolipoprotein B-100 in obesity. , 2000, Journal of lipid research.

[3]  C. Ludlam,et al.  The effects of low‐dose testosterone treatment on lipid metabolism, clotting factors and ultrasonographic ovarian morphology in women , 1998, Clinical endocrinology.

[4]  P. Schnohr,et al.  Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. , 1998, The New England journal of medicine.

[5]  A. Tall,et al.  Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia. , 1998, Journal of lipid research.

[6]  M. Savolainen,et al.  R451Q mutation in the cholesteryl ester transfer protein (CETP) gene is associated with high plasma CETP activity. , 1998, Atherosclerosis.

[7]  J W Jukema,et al.  The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. , 1998, The New England journal of medicine.

[8]  G. Jensen,et al.  Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. , 1997, Circulation.

[9]  M. McQueen,et al.  Mutations in cholesteryl ester transfer protein and hepatic lipase in a North American population. , 1997, Clinical biochemistry.

[10]  S. Yamashita,et al.  Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[11]  T. Sørensen,et al.  ACE gene polymorphism: ischemic heart disease and longevity in 10,150 individuals. A case-referent and retrospective cohort study based on the Copenhagen City Heart Study. , 1997, Circulation.

[12]  S. Yamashita,et al.  Molecular genetics of plasma cholesteryl ester transfer protein. , 1997, Current opinion in lipidology.

[13]  A. Tall,et al.  Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. , 1996, The Journal of clinical investigation.

[14]  D. Arveiler,et al.  Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction. , 1995, The Journal of clinical investigation.

[15]  Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[16]  P. Barter,et al.  CHOLESTERYL ESTER TRANSFER PROTEIN: ITS ROLE IN PLASMA LIPID TRANSPORT , 1994, Clinical and experimental pharmacology & physiology.

[17]  P. Barter,et al.  High-density lipoproteins and coronary heart disease. , 1991, Journal of cardiovascular risk.

[18]  A. Tall,et al.  Identification of a sequence within the C-terminal 26 amino acids of cholesteryl ester transfer protein responsible for binding a neutralizing monoclonal antibody and necessary for neutral lipid transfer activity. , 1992, The Journal of biological chemistry.

[19]  A. Tall,et al.  Organization of the human cholesteryl ester transfer protein gene. , 1990, Biochemistry.

[20]  A. Tall,et al.  Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipemic subjects. , 1990, The Journal of clinical investigation.

[21]  D. Gordon,et al.  High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. , 1989, Circulation.

[22]  C. Fielding,et al.  Cloning and sequencing of human cholesteryl ester transfer protein cDNA , 1987, Nature.